Catalog No.: PC-49222Not For Human Use, Lab Use Only.
KPT-276 (KPT276) is an orally bioavailable selective inhibitor of nuclear export (SINE) that irreversibly bind to CRM1 and block the function of this protein, shows antileukemic activity in vitro and in vivo in acute myeloid leukemia (AML).
KPT-276 (KPT276) is an orally bioavailable selective inhibitor of nuclear export (SINE) that irreversibly bind to CRM1 and block the function of this protein, shows antileukemic activity in vitro and in vivo in acute myeloid leukemia (AML).
KPT-276 inhibits a panel of AML cell lines proliferation (MV4-11, Kasumi-1, OCI/AML3, MOLM-13, KG1a, and THP-1) with IC50 of 100-500 nM.
KPT-276 decreases CRM1 protein level and accumulates CRM1 cargo proteins in the nucleus.
KPT-276 induces differentiation of AML cell lines.
KPT-276 (150 mg/kg) increases survival in a human leukemia xenograft model.
